FDA Blocks More Olympus Endoscopes and Imaging Devices from Entering the US
On October 20, 2026, the U.S. Food and Drug Administration alerted health care providers that it expanded an import alert blocking shipments of certain medical devices made in Japan by Olympus Medical Systems Corporation and its subsidiaries. The action, taken under Import Alert 89-04, prevents new models from entering the United States because of unresolved violations of quality system regulations. The newly added devices include enteroscopes and ingestible telemetric capsule imaging systems, joining dozens of bronchoscopes, ureterorenoscopes, laparoscopes, and automated endoscope reprocessors restricted since June 24, 2025. Patients undergoing diagnostic or surgical procedures in the urinary tract, lungs, abdomen, or digestive tract could be examined with Olympus tools. The agency advised clinicians that devices already in clinical settings can remain in use if they show no problems or leaks. The FDA also advised providers not to cancel or delay medical procedures without talking through the risks and benefits with their patients.
What was announced
The U.S. Food and Drug Administration issued an updated letter to health care providers regarding Import Alert 89-04. The alert bars specific medical devices produced in Japan by Olympus Medical Systems Corporation and its subsidiaries from entering the United States.
The FDA cited ongoing concerns with quality system regulation violations, which set baseline manufacturing standards for medical hardware. This update adds five device models to the import ban effective October 20, 2026:
- The Endocapsule Small Intestinal Capsule Endoscope Set (MAJ-2027)
- The Evis Exera II Small Intestinal Videoscope (SIF-Q180)
- The Endoeye Flex Deflectable Videoscope (LTF-S190-10)
- Two bronchovideoscopes (models BF-1TH1100 and BF-H1100)
These tools join an earlier list of restricted products dating back to June 24, 2025, which covers automated endoscope reprocessors, bronchoscopes, laparoscopes, and ureterorenoscopes. Related items like replacement parts, connectors, and single-use consumables are not included in the import alert.
What it means
Hospitals and clinics cannot import new units of the listed devices into the country.
Facilities already using these tools do not need to pull them immediately. The FDA stated that staff may continue operating existing devices if they function without problems. Workers must strictly clean and reprocess them according to instructions and perform scheduled maintenance. Any instrument that is damaged or fails a leak test must be removed from use to avoid potential contamination.
The FDA noted that some affected devices were previously recalled. In those situations, clinicians must follow Olympus's recall instructions. The regulator also recommended that doctors talk with patients about benefits and risks before postponing or canceling any scheduled procedures.
What the announcement does not tell us
The alert does not describe the specific quality system violations found at Olympus manufacturing plants.
The agency also does not share how many total units are currently in use across American hospitals. It does not state whether device shortages might occur as a result of the import halt, nor does it specify what steps Olympus must complete before the FDA will lift the import restrictions.
How this was written
This analysis was written with AI from the official announcement below, using only facts that announcement states. The quoted wording is FDA MedWatch Safety Alerts’s own. Always check the original before acting on anything here.
The U.S. Food and Drug Administration (FDA) is alerting health care providers about import alerts for certain medical devices manufactured in Japan by Olympus Medical Systems Corporation (Olympus) and its subsidiaries.
Opens www.fda.gov
More from FDA MedWatch Safety Alerts
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.